Search References Drug Actions/Targets About Access data Feedback
Sign In
mitontu@gmail.com
2021 MitoTox | (CC BY-NC 4.0)
Compound

D0289 | Oligomycin

Molecular Formula C45H74O11
Molecular Weight 791.1
Structure
Description polyketide inhibitors of F0F1-ATPase; macrolides created by Streptomyces; inhibits ATP synthase by blocking its proton channel (Fo subunit),

Toxicity Dose Time Species Model Method Action Positive criterion Reference
OXYGEN CONSUMPTION RATE (OCR) 0.92± 0.18 μM 2 minutes human HepG2 Measurement of OCR decrease EC50 7
ELECTRON TRANSPORT CHAIN 8 nM bovine heart mitochondria Measurement of complex V activity decrease IC50 3
ELECTRON TRANSPORT CHAIN decrease 35
ELECTRON TRANSPORT CHAIN 152 μg inhibitor/mg protein E. coli membrane vesicle, pH gradient formation affect 170
ELECTRON TRANSPORT CHAIN 7.1 μg inhibitor/mg protein C. asciculate SMP-ATPase affect IC50 170
ELECTRON TRANSPORT CHAIN 2.0-3.0 μg inhibitor/mg protein S. cerevisiae SMP-ATPase affect IC50 170
ELECTRON TRANSPORT CHAIN 0.3 μM human NCI-60 cell lines F0F1-ATPase affect IC50 170
ELECTRON TRANSPORT CHAIN 15 ng inhibitor/mg protein N. crassa SMP-ATPase affect Ki 170
ELECTRON TRANSPORT CHAIN 0.21 μM bovine heart MF0F1-ATPase affect Ki 170
ELECTRON TRANSPORT CHAIN 0.4 μg inhibitor/mg protein bovine heart SMP-ATPase affect 95% inhibition 170
ELECTRON TRANSPORT CHAIN 0.5 μg/ml rat liver SMP-ATPase affect 75% inhibition 170
ELECTRON TRANSPORT CHAIN 152 μg inhibitor/mg protein E. coli membrane vesicle decrease IC50 152
ELECTRON TRANSPORT CHAIN 7.1 μg inhibitor/mg protein C. asciculate SMP-ATPase decrease IC50 131
ELECTRON TRANSPORT CHAIN 2.0-3.0 μg inhibitor/mg protein S. cerevisiae SMP-ATPase decrease IC50 153
ELECTRON TRANSPORT CHAIN 0.3 μM human NCI-60 cell lines, F0F1-ATPase decrease IC50 154
ELECTRON TRANSPORT CHAIN 15 ng inhibitor/mg protein N. crassa SMP-ATPase decrease Ki 155
ELECTRON TRANSPORT CHAIN 0.21 μM bovine heart MF0F1-ATPase decrease Ki 156
ELECTRON TRANSPORT CHAIN 0.4 μg inhibitor/mg protein bovine heart SMP-ATPase decrease 95% inhibition 157
ELECTRON TRANSPORT CHAIN 0.5 μg/ml rat liver SMP-ATPase decrease 75% inhibition 158
ECAR 1.1±0.23 μM 2 minutes human HepG2 Measurement of ECAR increase EC50 7
GLUCOSE GALACTOSE IC50 RATIO 8.7 LUHMES (Lund human mesencephalic) cells Glc–Gal–NeuriTox assay EC25(NA) [Glc/Gal] 326
APOPTOSIS 0.3 μM 60 human cancer cell lines of the National Cancer Institute mean 184

Target Dose Time Species Model Method Action Positive criterion Reference
ATP synthase 8 nM bovine heart mitochondria Measurement of complex V activity inhibitor IC50 3
ATP synthase inhibitor 35
ATP synthase 152 μg inhibitor/mg protein E. coli membrane vesicle inhibitor IC50 152
ATP synthase 7.1 μg inhibitor/mg protein C. asciculate SMP-ATPase inhibitor IC50 131
ATP synthase 2.0-3.0 μg inhibitor/mg protein S. cerevisiae SMP-ATPase inhibitor IC50 153
ATP synthase 0.3 μM human NCI-60 cell lines, F0F1-ATPase inhibitor IC50 154
ATP synthase 15 ng inhibitor/mg protein N. crassa SMP-ATPase inhibitor Ki 155
ATP synthase 0.21 μM bovine heart MF0F1-ATPase inhibitor Ki 156
ATP synthase 0.4 μg inhibitor/mg protein bovine heart SMP-ATPase inhibitor 95% inhibition 157
ATP synthase 0.5 μg/ml rat liver SMP-ATPase inhibitor 75% inhibition 158
ATP synthase 8.7 LUHMES (Lund human mesencephalic) cells Glc–Gal–NeuriTox assay EC25(NA) [Glc/Gal] 326
Fo subunits 152 μg inhibitor/mg protein E. coli membrane vesicle, pH gradient formation inhibitor 170
Fo subunits 7.1 μg inhibitor/mg protein C. asciculate SMP-ATPase inhibitor IC50 170
Fo subunits 2.0-3.0 μg inhibitor/mg protein S. cerevisiae SMP-ATPase inhibitor IC50 170
Fo subunits 0.3 μM human NCI-60 cell lines F0F1-ATPase inhibitor IC50 170
Fo subunits 15 ng inhibitor/mg protein N. crassa SMP-ATPase inhibitor Ki 170
Fo subunits 0.21 μM bovine heart MF0F1-ATPase inhibitor Ki 170
Fo subunits 0.4 μg inhibitor/mg protein bovine heart SMP-ATPase inhibitor 95% inhibition 170
Fo subunits 0.5 μg/ml rat liver SMP-ATPase inhibitor 75% inhibition 170

Pictogram Signal Statements Precautionary Statement Codes
Warning

The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.


H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]


 P264, P270, P301+P312, P330, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.)
Warning

Aggregated GHS information provided by 193 companies from 1 notifications to the ECHA C&L Inventory.


H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]


Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.


 P264, P270, P301+P312, P330, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.)

Organism Test type Route Dose (normalized dose) Effect Source
mouse LD50 intraperitoneal 1500ug/kg (1.5mg/kg) Journal of the American Chemical Society. Vol. 80, Pg. 6092, 1958.


  • EINECS 215-767-9 LS-98326 Oligomycin
    SCHEMBL4362703

    CAS Number 579-13-5
    PubChem Compound 6450197
    ChEBI 28285
    ChemSpider 21106358
    Wikipedia Oligomycin